| mRNA |
Cisplatin |
GDSC1000 |
pan-cancer |
AAC |
0.0047 |
0.9 |
| mRNA |
Vandetanib |
CCLE |
pan-cancer |
AAC |
-0.0061 |
0.9 |
| mRNA |
BRD-K42260513 |
CTRPv2 |
pan-cancer |
AAC |
0.0072 |
0.9 |
| mRNA |
JQ-1:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0043 |
0.9 |
| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0041 |
0.9 |
| mRNA |
Doxorubicin |
gCSI |
pan-cancer |
AAC |
-0.0063 |
0.9 |
| mRNA |
tivantinib |
CTRPv2 |
pan-cancer |
AAC |
0.0055 |
0.9 |
| mRNA |
QL-XII-61 |
GDSC1000 |
pan-cancer |
AAC |
0.0057 |
0.9 |
| mRNA |
Bortezomib |
CTRPv2 |
pan-cancer |
AAC |
0.004 |
0.9 |
| mRNA |
SNS-032 |
CTRPv2 |
pan-cancer |
AAC |
0.0041 |
0.9 |